! HOT TOPIC - Time matters in AHF.
EUSEM eLearning. Peacock F. Sep 11, 2018; 227586; 38512 Disclosure(s): Research Grants: Abbott, Braincheck, Immunarray, Janssen, Ortho Clinical Diagnostics, Relypsa, Roche, ZS Pharma
Consultant: Abbott, Astra-Zeneca, Bayer, Beckman, Boehrhinger-Ingelheim, Ischemia Care, Dx, Immunarray, Instrument Labs, Janssen, Ortho Clinical Diagnostics, Relypsa, Quidel, Roche, Siemens. Expert Testimony: Johnson and Johnson. Ownership Interests: AseptiScope, Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Ischemia DX, LLC.
Prof. Frank Peacock
Prof. Frank Peacock
Only EUSEM-Members and Congress 2018 participants have access to the Congress 2018 content. To become a member click here
Abstract
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation, the participant will be able to:
- Identify the time-dependent benefit of HF treatment
- Discuss the relative magnitude of the time to treatment and outcome effects in acute heart failure
- Adopt a strategy of rapid evaluation and treatment in suspected Acute Heart Failure patients presenting to the ER
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies